4.6 (157) In stock
A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.
Bivalent CoV2 preS dTM-AS03 (D614 + Beta) induces broader
Cross-variant neutralization of SARS-CoV-2 isolates from human
Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants – ScienceOpen
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
MVA-vectored universal beta-coronavirus vaccine design & development
Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants
Monovalent and bivalent mRNA vaccines encoding ancestral, Beta and
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection, Journal of Biomedical Science
How to interpret new studies on coronavirus variants
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 - ScienceDirect
The bivalent vaccine D614 + Beta elicits cross-neutralization of the
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Vaccines, Free Full-Text
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants - Liang - 2024 - Journal of Medical Virology - Wiley Online Library
